Реферат
Objective:To compare the simplicity, safety, efficacy, prognoses and economic burden of CAS-R-2 frameless stereotactic device and Leksell frame stereotactic device in assisting surgery for patients with hypertensive cerebral hemorrhage (ICH, hematoma volume: 20-40 mL).Methods:The clinical data of 120 patients with supratentorial ICH, admitted to our hospital from December 2012 to December 2019, were retrospectively analyzed; trepanation and drainage assisted by CAS-R-2 frameless stereotactic device was performed in 65 patients (frameless group), and trepanation and drainage assisted by Leksell frame stereotactic device was performed in 55 patients (frame group). The differences of surgery time, hematoma evacuation rate 7 d after surgery, incidences of recurrent hemorrhage and intracranial infection during hospitalization, length and expense of hospitalization, and modified Rankin scale (mRs) scores 6 months after surgery were compared between the two groups.Results:As compared with those in the frame group, patients from the frameless group had significantly shorter surgery time ([0.5±0.1] h vs. [2.2±0.5] h), significantly lower incidence of recurrent hemorrhage (0% vs. 9.1%) and significantly lower incidence of intracranial infection (1.5% vs. 9.1%) during hospitalization ( P<0.05). The hospitalization expense of patients from the frame group was significantly lower than that in the frameless group ( P<0.05). There were no significant differences in hematoma evacuation rate 7 d after surgery, length of hospital stays, and mortality and mRs scores 6 months after treatment between the two groups ( P>0.05). Conclusion:For patients with supratentorial ICH, trepanation and drainage assisted by CAS-R-2 frameless stereotactic device has the same curative effect and prognoses as Leksell frame stereotactic one; the former has higher simplicity and clinical safety, and the latter has lower economic burden.
Реферат
Objective:To analyze the clinical characteristics and diagnosis and treatment experiences of Langerhans cell histocytosis (LCH) in skull.Methods:Sixteen patients with cranial LCH admitted to our hospital from January 2015 to December 2019 were chosen in our study. Their clinical data, diagnosis and treatment procedures and prognoses were retrospectively analyzed.Results:Among the 16 patients, there were 13 males and 3 females, aged from 1 to 31 years. The clinical manifestations included space-occupying lesions of the skull; and imaging showed bone destruction of the skull, with or without involvement of other bones or organs. All patients were pathologically confirmed to have LCH after surgical total resection of the lesions. Routine whole-body bone scanning was performed after surgery: one was found to have local abnormal metabolic activity and received local radiotherapy; 8 were combined with other bone or organ involvement, and received chemotherapy. All the patients were followed up for 1-5 years, and no recurrence was found, and no one died.Conclusion:Good prognosis can be achieved in cranial LCH patients accepted resection by giving additional treatment according to the results of postoperative reexamination and combination use of standardized radiotherapy and chemotherapy.